Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

Share Price is delayed by 15 minutes
Get Live Data
0.18    -0.022 (-10.89%)
Bid:
0.17
Ask:
0.19
Spread: 0.02 (11.765%)
Market Cap: £4.70m
NFX Live PriceLast checked at - London Stock Exchange

Intraday Nuformix Share Chart

Holding(s) in Company

22 Oct 2020 16:16

RNS Number : 9641C
Nuformix PLC
22 October 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Nuformix plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

CPI Enterprises Limited

City and country of registered office (if applicable)

UK

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

21 October 2020

6. Date on which issuer notified (DD/MM/YYYY):

21 October 2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

39,360,000

7.7%

513,359,368

Position of previous notification (if

applicable)

43,360,000

8.8%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BYW79Y38

39,360,000

7.7%

SUBTOTAL 8. A

39,360,000

7.7%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

x

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

Wilton, UK

Date of completion

21 October 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFEDFIEESSEFS
Date   Source Headline
28th May 20267:00 amRNSHalf Year Report
31st Mar 20267:00 amRNSTotal Voting Rights
11th Mar 20267:00 amRNS£1.0 million Placing
10th Mar 20267:00 amRNSConfirmation of US ODD for NXP002 in IPF
3rd Mar 202610:05 amRNSResult of AGM
5th Feb 202612:00 pmRNSPosting of Annual Report and Notice of AGM
27th Jan 20267:00 amRNSAnnual Results for period ended 30 September 2025
28th Nov 20253:22 pmRNSTotal Voting Rights
12th Nov 20257:01 amRNSUpdate re. US FDA ODD Application
12th Nov 20257:00 amRNSResults of Underwritten Open Offer
28th Oct 20257:00 amRNSUnderwritten Open Offer
10th Oct 20257:00 amRNSChange of Auditor
25th Sep 20257:00 amRNS-REuropean Respiratory Society Congress Attendance
11th Aug 20257:00 amRNSUS FDA ODD Application Submitted for NXP002
30th May 20252:24 pmRNSTotal Voting Rights
29th May 20257:00 amRNSConfirmation of European ODD for NXP002
23rd May 20251:08 pmRNSPublication of a Prospectus
22nd May 20257:00 amRNS£210,000 Placing
19th May 20257:00 amRNS-RAttendance at American Thoracic Society Congress
2nd May 20257:00 amRNSHalf-year Report
30th Apr 20257:00 amRNSConfirmation of European Orphan Drug Designation
29th Apr 20257:00 amRNSChange of Registered Office and Company Secretary
14th Apr 20257:00 amRNSExercise of Warrants
9th Apr 20257:00 amRNSNXP002 Update
20th Mar 202511:10 amRNSResult of AGM
28th Feb 202512:30 pmRNSTotal Voting Rights
14th Feb 20252:18 pmRNSPosting of Annual Report and Notice of AGM
30th Jan 20257:00 amRNS£168,750 Placing
29th Jan 20257:00 amRNSAnnual Results for period ended 30 September 2024
28th Jan 20257:00 amRNSNXP002 ODD Application Submitted
13th Jan 20257:00 amRNSNXP002 Orphan Drug Designation Draft Application
29th Nov 20245:00 pmRNSTotal Voting Rights
5th Nov 20242:25 pmRNSDirector/PDMR Dealings
4th Nov 202410:17 amRNSResult of General Meeting
16th Oct 20241:37 pmRNSPublication of Prospectus & Notice of GM
20th Sep 20242:24 pmRNS£300,000 Fundraise
18th Jun 20247:00 amRNSHalf-year Report
17th Jun 20247:00 amRNSPatent Update
19th Mar 20242:39 pmRNSResult of AGM
1st Mar 20247:00 amRNSSubscription to raise £150,000
15th Jan 202411:30 amRNSPosting of Annual Report and Notice of AGM
3rd Jan 20247:00 amRNSResults for the period ended 30 September 2023
18th Dec 20237:00 amRNSNXP001 Update
23rd Oct 20237:00 amRNSNotice of Allowance of NXP002 Patent in Japan
18th Sep 20237:00 amRNSNXP001 Update
24th Aug 20231:22 pmRNSResult of Annual General Meeting
31st Jul 20232:00 pmRNSNotice of AGM
26th Jul 20232:55 pmRNSHolding(s) in Company
2nd Jun 20237:00 amRNSInvestor Online Q&A
25th May 20237:00 amRNSChange of Auditor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.